Drug Avifavir na Rasha yana Tasiri Akan COVID-19 Bambance-bambancen

Bugu da kari, kwayar cutar ba ta da ikon haɓaka juriya ga favipiravir har ma da ɗaukar dogon lokaci akan ƙwayoyin cuta, kamar yadda aka tabbatar a cikin gwaji na asibiti. Wannan yana ba da Avifavir tare da babbar fa'ida ba kawai akan takamaiman takamaiman ilimin halittu ba har ma da sauran samfuran nucleoside iri ɗaya masu kama da haifar da saurin juyin halitta na bambance-bambancen asibiti.

Matsalar saurin maye gurbi ta musamman ce ta ƙwayoyin cuta ta RNA, kamar SARS-CoV-2 (coronavirus). Yawancin maye gurbi ana samun su a cikin tsarin furotin mai karu, musamman a cikin mahimman sassansa guda biyu waɗanda tsarin garkuwar ɗan adam ya gane.

Binciken meta na nazarin jiyya guda 23 na COVID-19 don favipiravir yana nuna haɓaka 47% lokacin da ake amfani da favipiravir a farkon maganin coronavirus. Ana samun wannan bincike a: https://c19favipiravir.com/meta.html

A watan Yuni 2020, tare da tallafin Asusun Zuba Jari kai tsaye na Rasha (RDIF, asusun arziƙi na Rasha), ƙwararrun ChemRar Group sun haɓaka kuma sune farkon a cikin duniya don sakin Avifavir (INN: favipiravir), maganin rigakafi kai tsaye don maganin COVID-19. , zuwa kasuwannin Rasha da na duniya. An tabbatar da ingancin samfurin a cikin cikakken gwajin asibiti a Rasha wanda ya ƙunshi marasa lafiya 460 na COVID. An ba da Avifavir® zuwa fiye da ƙasashe 15 na duniya.

Gwajin gwaji na asibiti na Avifavir sun nuna kaddarorin sa na rigakafin COVID, kamar rage alamun bayyanar cututtuka da yanke tsawon lokacin cutar da rabi idan aka kwatanta da daidaitaccen magani.

A musamman:

• Avifavir yana nuna kyakkyawan sakamako a cikin maganin COVID lokacin amfani da shi a cikin kwanaki 3-5 na farko bayan alamun farko;

• Bayan kwanaki 4 na farko na jiyya, 65% na marasa lafiya a kan Avifavir sun gwada rashin lafiyar coronavirus, ninki biyu na daidaitattun rukunin jiyya. A rana ta 10, adadin marasa lafiya marasa lafiya sun kai 90%;

• A cikin 68% na marasa lafiya a kan Avifavir, zafin jiki ya daidaita a baya (a ranar 3) idan aka kwatanta da ƙungiyar kulawa (a ranar 6).

• Lokacin tsaka-tsaki don haɓakar asibiti tare da Avifavir shine kwanaki 7 da kwanaki 10 a cikin ƙungiyar kulawa ta yau da kullun.

Bugu da ƙari, sakamakon Avifavir a cikin marasa lafiya tare da COVID-19 ana sa ido sosai a cikin aikin asibiti na ainihi. A halin yanzu ana kan aiwatar da bita na baya-bayan nan game da inganci da amincin favipiravir a cikin marasa lafiya 40,000 da aka fallasa samfurin a wurin marasa lafiya ko marasa lafiya.

A cikin 2020-2021, yuwuwar favipiravir akan kamuwa da cutar coronavirus an bincika sosai a cikin gwaje-gwajen asibiti sama da 50 da suka shafi kusan marasa lafiya 5,000 a Rasha, Japan, China, India, Thailand, Turkey, Iran, Saudi Arabia, ƙasashen EU da Latin Amurka. Ya zuwa yau, bayanan PubMed na wallafe-wallafen likitanci na duniya da na ilimin halitta ya ƙunshi takardu masu alaƙa da favipiravir kusan 900. Akalla 700 daga cikinsu an buga su a cikin shekaru 1.5 na ƙarshe. Waɗannan littattafan suna magana ne don babban inganci da amincin favipiravir akan COVID-19.

Har zuwa yau, an tattara tarin bayanai masu yawa a cikin wallafe-wallafen kimiyya game da bangarori daban-daban na favipiravir pharmacology kamar yadda samfurin ya yi nazari sosai, ciki har da hanyoyin aiwatar da aiki, aiki a cikin vitro da in vivo, ingantaccen asibiti, aminci, ƙimar farashi. , yuwuwar maganin haɗin gwiwa, hanyoyin sarrafa nazari, da sauransu. Jerin gwaje-gwaje na asibiti a cikin 2020-2021 sun ba da tabbataccen shaida don inganci da amincin favipiravir azaman jiyya don COVID-19.

Idan farfesa ya fara a cikin kwanaki na farko bayan bayyanar cututtuka, samfurin yana haɓaka ƙimar rayuwa sosai, yana rage nauyin ƙwayar cuta, buƙatar samun iska ta wucin gadi, da tsawon zaman asibiti.